pharma · Lymphoma of B-cell origin · Malignant Solid Tumors
Genmab
Genmab A/S
Genmab A/S is a pharma organization headquartered in Valby, DK. Primary therapeutic focus areas include Lymphoma of B-cell origin, Malignant Solid Tumors, Metastatic or advanced malignant solid tumors, Non-Small Cell Lun
Carl Jacobsens Vej 30, 2500 Valby, DK HQ
2,847 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Carl Jacobsens Vej 30, 2500 Valby, DK
- Employees
- 2,847
- Programs
- 29
- Drugs
- 56
- Patents
- 0
GCT3013-05
Phase 3 · small molecule · B-cell Lymphoma
GCT3013-05 for B-cell Lymphoma is a Phase 3 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).
Internal code GCT3013-05
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Genmab A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- B-cell Lymphoma
- Status
- active
- Trials
- 1